Alaunos ended the fourth quarter of 2022 with unaudited cash and cash equivalents of approximately $39.1 million and restricted cash of approximately $13.9 million. Based on current operating plans, the Company expects its operating cash flow for 2023 to be between approximately $35 million and $40 million. The Company expects to have sufficient cash resources to fund research and development programs and operations into Q4 2023.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TCRT:
- Alaunos Therapeutics Highlights Strategic Priorities and Anticipated Portfolio Milestones for 2023
- Alaunos Therapeutics 24.228M share Spot Secondary priced at 65c
- Alaunos Therapeutics announces pricing of public offering of common stock
- Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock
- Alaunos Therapeutics files to sell common stock, no amount given